OBJECTIVES: The objectives of this study were to establish a bisphosphonate-related osteonecrosis of the jaw (BRONJ) rat model and to analyse the effects of teriparatide (TP) on this model. METHODS: Sprague-Dawley rats were divided into three groups: I-zoledronic acid (ZA, n = 10); II-ZA and teriparatide (ZA + TP, n = 10); III-control (n = 10). Osteonecrosis was induced by administering zoledronic acid to groups ZA and ZA + TP. A week after the injections, rats underwent extraction of the first left mandibular molar. Following a four week period, TP was administered to the ZA + TP group for 28 days. Upon killing, extraction sockets were examined clinically, radiologically and histopathologically. RESULTS: Clinical examination revealed necrotic bone exposure in none of the animals. MicroCT (µCT) examination showed that bone mineral density of the newly formed bone in the extraction socket was lower in the ZA group than in the ZA + TP group (p < 0.05). Histopathological examination revealed that only the ZA and ZA + TP groups developed osteonecrosis, and the osteonecrotic bone area in the ZA group was larger than that in the ZA + TP group (p < 0.05). Tartrate-resistant acid phosphatase (TRAcP) enzyme histochemistry revealed that the number of detached and large osteoclasts were higher in the ZA group than in other groups, whereas the number of apoptotic osteoclasts in both ZA and ZA + TP groups were higher than in the control group (p < 0.05). CONCLUSIONS: Our data indicate that bisphosphonate-related osteonecrosis of the jaw model used in the present study is an attractive model to investigate treatment modalities and that TP might be an effective treatment in BRONJ.
OBJECTIVES: The objectives of this study were to establish a bisphosphonate-related osteonecrosis of the jaw (BRONJ) rat model and to analyse the effects of teriparatide (TP) on this model. METHODS:Sprague-Dawley rats were divided into three groups: I-zoledronic acid (ZA, n = 10); II-ZA and teriparatide (ZA + TP, n = 10); III-control (n = 10). Osteonecrosis was induced by administering zoledronic acid to groups ZA and ZA + TP. A week after the injections, rats underwent extraction of the first left mandibular molar. Following a four week period, TP was administered to the ZA + TP group for 28 days. Upon killing, extraction sockets were examined clinically, radiologically and histopathologically. RESULTS: Clinical examination revealed necrotic bone exposure in none of the animals. MicroCT (µCT) examination showed that bone mineral density of the newly formed bone in the extraction socket was lower in the ZA group than in the ZA + TP group (p < 0.05). Histopathological examination revealed that only the ZA and ZA + TP groups developed osteonecrosis, and the osteonecrotic bone area in the ZA group was larger than that in the ZA + TP group (p < 0.05). Tartrate-resistant acid phosphatase (TRAcP) enzyme histochemistry revealed that the number of detached and large osteoclasts were higher in the ZA group than in other groups, whereas the number of apoptotic osteoclasts in both ZA and ZA + TP groups were higher than in the control group (p < 0.05). CONCLUSIONS: Our data indicate that bisphosphonate-related osteonecrosis of the jaw model used in the present study is an attractive model to investigate treatment modalities and that TP might be an effective treatment in BRONJ.
Entities:
Keywords:
Microcomputed tomography; bisphosphonate-associated osteonecrosis of the jaw; tartrate-resistant acid phosphatase; teriparatide; zoledronic acid
Authors: Robert E McMahon; Jerry E Bouquot; Charles J Glueck; John A Griep; William R Adams; Kenneth J Spolnik; Kevin A Deardorf Journal: J Oral Maxillofac Surg Date: 2007-09 Impact factor: 1.895
Authors: Yanfei L Ma; Henry U Bryant; Qingqiang Zeng; Allen Schmidt; Jennifer Hoover; Harlan W Cole; Wei Yao; Webster S S Jee; Masahiko Sato Journal: Endocrinology Date: 2003-05 Impact factor: 4.736
Authors: Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane Journal: J Bone Miner Res Date: 2007-10 Impact factor: 6.741
Authors: A M Pabst; M Krüger; K Sagheb; T Ziebart; C Jacobs; S Blatt; E Goetze; C Walter Journal: Clin Oral Investig Date: 2016-05-12 Impact factor: 3.573
Authors: Giovanni Mergoni; Paolo Vescovi; Roberto Sala; Elisabetta Merigo; Pietro Passerini; Roberta Maestri; Domenico Corradi; Paolo Govoni; Samir Nammour; Massimiliano G Bianchi Journal: Support Care Cancer Date: 2015-07-21 Impact factor: 3.603
Authors: R Nicole Howie; James L Borke; Zoya Kurago; Asma Daoudi; James Cray; Ibrahim E Zakhary; Tara L Brown; J Nathan Raley; Loan T Tran; Regina Messer; Fardous Medani; Mohammed E Elsalanty Journal: PLoS One Date: 2015-07-17 Impact factor: 3.240
Authors: Henrik Holtmann; Julian Lommen; Norbert R Kübler; Christoph Sproll; Majeed Rana; Patrick Karschuck; Rita Depprich Journal: J Int Med Res Date: 2018-08-09 Impact factor: 1.671